Carasent Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Carasent heeft een totaal eigen vermogen van NOK945.6M en een totale schuld van NOK0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk NOK1.1B en NOK148.2M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

NOK 0

Schuld

Rente dekkingsratio	n/a
Contant	NOK 362.42m
Aandelen	NOK 945.62m
Totaal verplichtingen	NOK 148.21m
Totaal activa	NOK 1.09b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NOK429.6M ) C34 } overtreffen de korte termijn passiva ( NOK104.2M ).

Langlopende schulden: De kortetermijnactiva C34 ( NOK429.6M ) overtreffen de langetermijnschulden ( NOK44.1M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: C34 is schuldenvrij.

Schuld verminderen: C34 heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 2.6% was.

Schuldendekking: C34 heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: C34 heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

Carasent Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Carasent ASA (OB:CARA) acquired Data - Al GmbH.

Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.06 loss in 3Q 2023)

New minor risk - Share price stability

High number of new and inexperienced directors

Eg Norge A/S cancelled the acquisition of Carasent ASA (OB:CARA).

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)

Chief Executive Officer recently bought €121k worth of stock

Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022)

Founder recently bought €2.4m worth of stock

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Carasent Asa Approves Dividend

Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022)

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Full year 2022 earnings released

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

High number of new and inexperienced directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: kr0.13 (vs kr0.28 loss in 3Q 2021)

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Second quarter 2022 earnings released: EPS: kr0.03 (vs kr0.34 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: kr0.32 (vs kr0.14 loss in 1Q 2021)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings released: kr0.002 loss per share (vs kr0.85 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)

Full year 2020 earnings released: kr0.85 loss per share (vs kr0.079 profit in FY 2019)

Aeternum Capital AS, a fund managed by Aeternum Management AS acquired 15% stake in Carasent ASA (OB:CARA).

Revenue misses expectations

New 90-day high: €3.76

Carasent ASA, Annual General Meeting, Jun 03, 2021

New 90-day high: €3.42

Carasent ASA Appoints Dennis Höjer as CEO

Carasent ASA (OB:CARA) acquired Avans Soma AS from Rieber & Søn ASA and others for approximately NOK 120 million.

New 90-day high: €2.59

Third quarter earnings released

Third quarter earnings released

Chairman recently sold €2.1m worth of stock

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven